by Sean Hughes | May 11, 2026 | EPO
Sequence Identity Claims After T 0137/24 The recent Board of Appeal decision in T 0137/24 provides useful guidance on how sequence identity claims are assessed under the EPC, particularly in relation to added matter and sufficiency. Biotech sequence-related claims are...
by Alyson Lam | Apr 29, 2026 | EPO
Summary of T 439/22 This decision represents a further development of the earlier T 439/22 proceedings, which led to the G1/24 referral to the EPO’s Enlarged Board of Appeal (EBA). The decision of the EBA was reported in our previous article. To recap, granted claim 1...
by Luke Pettit | Jan 15, 2026 | UPC
Background The UPC Court of Appeal’s decision in Otec v. Steros provides an interesting insight into claim interpretation and the constraints on relying on post-filing experimental evidence at the UPC. The case, UPC Court of Appeal decision 579/2025, arose from a...
by Juliette Boynton | Oct 15, 2025 | EPO
As a reminder, following grant of a patent to Foreo AB an opposition was filed by Beurer GmbH, and during the pendency of the opposition, Foreo sent a letter to Geske GmbH & Co. KG accusing them of infringment and threatening action. Geske filed an intervention...
by Sean Hutchinson | Sep 16, 2025 | EPO, Uncategorised
We reported in our article of June 2025 that the decision of the EPO’s Enlarged Board of Appeal in G 1/24 seemed likely to “force a monumental change in practice at the EPO, whose examiners are very unlikely to now be able to raise objections against the claims of a...
Recent Comments